Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

How Janssen’s twice-yearly schizophrenia drug could help patients

The long-acting form of drug paliperidone could help reduce the relapse rate for people with schizophrenia, according to a psychiatrist involved in the Phase 3 clinical trial for the drug.

By Brian Buntz | September 9, 2021

JanssenTraditionally, one of the most challenging aspects of treating schizophrenia is medication adherence. Patients who neglect to take their medicine have an elevated risk of relapse, hospitalization and suicide.

“There’s a higher likelihood of an exacerbation of the illness occurring,” said Dr. Gustavo Alva, medical director at ATP Clinical Research (Costa Mesa, California). 

The problem has led drug companies to develop long-acting formulations of antipsychotics. In that vein, Janssen (NYSE:JNJ) recently announced that it has scored FDA approval for the long-acting atypical antipsychotic Invega Hafyera (paliperidone palmitate). The drug is the first twice-yearly injectable treatment for adults with schizophrenia. 

[Related: Janssen wins FDA approval of twice-yearly schizophrenia treatment]

Paliperidone is the primary active metabolite of Risperdal (risperidone), which first won FDA approval in 1993. The first long-acting injectable of paliperidone palmitate was Risperdal Consta (risperidone), which FDA approved in 2003. Administered every two weeks, Risperdal Consta requires refrigeration.

“It was more laborious to utilize [than Invega],” said Alva, who was a clinical trial investigator for Invega Hafyera. 

FDA approved a monthly injectable form of paliperidone palmitate known as Invega Sustenna in 2009. “This was really a step forward for our patients,” Alva said. 

The agency approved a three-month formulation known as Invega Trinza in 2015, which is available for individuals who received Invega Sustenna for at least four months. 

With Invega Hafyera, psychiatrists could potentially tell patients, “we could get you to a point where you literally get your injection twice a year, and you’re set,” Alva said. 

Similarly, patients interested in Invega Hafyera must graduate from Sustena of Trinza formulations before receiving the twice-yearly formulations. 

The time window increases the likelihood that patients will be able to “maintain their wellness and not relapse,” Alva said. “That is truly transformational.” 

In a Phase 3 clinical trial, 92.5% of patients receiving Invega were relapse-free at 12 months, while 95% of those treated with Invega Trinza were. 

The safety profile for Invega Hafyera was consistent with that of Invega Sustenna and Invega Trinza. “There were no new safety signals,” Alva said.  

Alva notes that patients new to the drug may need to take an oral version of Invega Sustenna first to determine if they have a hypersensitivity reaction.

“You would not want to give somebody an injection of a medicine for which we didn’t know whether they were going to have an allergic reaction,” he said.

Patients must also be adequately treated with Invega Sustenna (one-month paliperidone palmitate) for at least four months, or Invega Trinza (three-month paliperidone palmitate) for at least one three-month injection cycle.


Filed Under: clinical trials, Drug Discovery
Tagged With: ATP Clinical Research, FDA, Invega, Invega Hafyera, Invega Sustenna, Invega Trinza, Janssen
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
How biosimulation and virtual trials can bust through clinical trial roadblocks
Complexity’s counterpoint: Understanding protocol optimization 
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE